Vi-CRM197 as a new conjugate vaccine against Salmonella Typhi

Vaccine

Volumn 29, Issue 4, 2011, Pages 712-720

  Micoli, F ^a   Rondini, S ^a   Pisoni, I ^a   Proietti, D ^a   Berti, F ^a   Costantino, P ^a   Rappuoli, R ^a   Szu, S ^b   Saul, A ^a   Martin, L B ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Conjugate vaccine; Salmonella Typhi; Vi

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIAL PROTEIN; CARRIER PROTEIN; DIPHTHERIA TOXIN; DIPHTHERIA TOXOID CRM197; TYPHOID VACCINE; UNCLASSIFIED DRUG; VIRULENCE CAPSULAR POLYSACCHARIDE; BACTERIUM ANTIBODY; CRM197 (NON TOXIC VARIANT OF DIPHTHERIA TOXIN); CRM197 (NON-TOXIC VARIANT OF DIPHTHERIA TOXIN); IMMUNOLOGICAL ADJUVANT; RICKETTSIA VACCINE; TYPHUS VACCINE; VACCINE; VI ANTIGEN;

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL STRAIN; CITROBACTER FREUNDII; DERIVATIZATION; DEVELOPING COUNTRY; DRUG CONJUGATION; DRUG FORMULATION; DRUG SYNTHESIS; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SALMONELLA TYPHI; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; FEMALE; IMMUNIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; METHODOLOGY; TYPHOID FEVER; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; CITROBACTER FREUNDII; FEMALE; IMMUNIZATION, SECONDARY; MICE; MICE, INBRED BALB C; POLYSACCHARIDES, BACTERIAL; RICKETTSIAL VACCINES; SALMONELLA TYPHI; TYPHOID FEVER; VACCINATION; VACCINES, CONJUGATE;

EID: 78650615093     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.022     Document Type: Article

References (48)

1. Crump J.A., Luby S.P., Minta E.D. The global burden of typhoid fever. Bull WHO 2004, 82(5):346-353.
2. Khan M.I., Ochiai R.L., Clemens J.D. Population impact of Vi capsular polysaccharide vaccine. Expert Rev Vaccines 2010, 9(5):485-496.
3. Ackers M.L., Puhr N.D., Tauxe R.V., Mintz E.D. Laboratory-based surveillance of Salmonella serotype Typhi infections in the United States: antimicrobial resistance on the rise. JAMA 2000, 283(20):2668-2673.
4. Lawrence J., Jones J. Final report: pilot of enhanced enteric fever surveillance in England, Wales, and Northern Ireland 2008 2008, Health Protection Agency, London, UK.
5. Saha S.K., Baqui A.H., Hanif M., Darmstadt G.L., Ruhulamin M., Nagatake T., et al. Typhoid fever in Bangladesh: implications for vaccination policy. Pediatr Infect Dis J 2001, 20(5):521-524.
6. Lin F.-Y.C., Ho V.A., Bay P.V., Thuy N.T.T., Bryla D., Thanh C.T., et al. The epidemiology of typhoid fever in the Dong Thap Province, MeKong Delta region of Vietnam. Am. J. Trop. Med. Hyg. 2000, 62:644-648.
7. Sinha A., Sazawal S., Kumar R., Sood S., Reddaiah V.P., Singh B., et al. Typhoid fever in children aged less than 5 years. Lancet 1999, 354:734-737.
8. Brooks W.A., Hossain A., Goswami D., Sharmeen A.T., Nahar K., Alam K., et al. Bacteremic typhoid fever in children in an urban slum, Bangladesh. Emerg Infect Dis 2005, 11:326-329.
9. Sur D., Ochiai R.L., Bhattacharya S.K., Ganguly N.K., Ali M., Manna B., et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. Engl J Med 2009, 23, 361(4):335-344.
10. Szu S.C., Li X., Stone A.L., Robbins J.B. Relation between structure and immunologic properties of the Vi capsular polysaccharide. Infect Immun 1991, 59(12):4555-4561.
11. DeRoeck D., Ochiai R.L., Yang J., Anh D.D., Alag V., Clemens J.D. Typhoid vaccination: the Asian experience. Expert Rev Vaccines 2008, 7(5):547-560.
12. Guzman C.A., Borsutzky S., Griot-Wenk M., Metcalfe I.C., Pearman J., Collioud A., et al. Vaccines against typhoid fever. Vaccine 2006, 24(18):3804-3811.
13. Fraser A., Goldberg E., Acosta C.J., Paul M., Leibovici L. Vaccines for preventing typhoid fever. Cochrane Database of Syst Rev 2007, (3). Art. No.: CD001261. 10.1002/14651858.CD001261.pub2.
14. Fraser A., Paul M., Goldberg E., Acosta C.J., Leibovici L. Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials. Vaccine 2007, 25(45):7848-7857.
15. World Health Organization Typhoid vaccines: WHO position paper. Wkly Epidemiol Rec 2008, 83(6):49-60.
16. Ada G., Isaacs D. Carbohydrate-protein conjugate vaccines. Clin Microbiol Infect 2003, 9:79-85.
17. Jones C. Vaccines based on the cell surface carbohydrates of pathogenic bacteria. An Acad Bras Cienc 2005, 77(2):293-324.
18. Szu S.C., Robbins J.B., Schneerson R., Lin F.Y. Polysaccharide-based conjugate vaccines for enteric bacterial infections: typhoid fever, non-typhoidal Salmonella and Escherichia coli O157:H7. New generation vaccines 2009, vol. 47. MM Levine Editor, p. 1040. 4th ed.
19. Canh D.G., Lin F., Thiem V.D., Trach D.D., Trong N.D., Mao N.D., et al. Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children. Infect Immun 2004, 72(11):6586-6588.
20. Lin F.Y., Ho V.A., Khiem H.B., Trach D.D., Bay P.V., Thanh T.C. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001, 344(17):1263-1269.
21. Croxtall J.D., Keating G.M. Pneumococcal polysaccharide protein D-conjugate vaccine (Synflorix; PHiD-CV). Paediatr Drugs 2009, 11(5):349-357.
22. Rennels M.B., Edwards K.M., Keyserling H.L., Reisinger K.S., Hogerman D.A., Madore D.V., Chang I., Paradiso P.R., Malinoski F.J., Kimura A. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 1998, 101(4 Pt 1):604-611.
23. Shinefield H.R., Black S., Ray P., Chang I., Lewis N., Fireman B., et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 1999, 18(9):757-763.
24. Snape M.D., Perrett K.P., Ford K.J., John T.M., Pace D., Yu L.M., et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008, 299(2):173.
25. Daniels E.M., Schneerson R., Egan W.M., Szu S.C., Robbins J.B. Characterization of the Salmonella paratyphi C Vi polysaccharide. Infect Immun 1989, 57(10):3159-3164.
26. Hale C., Bowe F., Pickard D., Clare S., Haeuw J.F., Powers U., et al. Evaluation of a novel Vi conjugate vaccine in a murine model of salmonellosis. Vaccine 2006, 24:4312-4320.
27. Kossaczka Z., Bystricky S., Bryla D.A., Shiloach J., Robbins J.B., Szu S.C. Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker. Infect Immun 1997, 65(6):2088-2093.
28. Szu S.C., Li X.R., Schneerson R., Vickers J.H., Bryla D., Robbins J.B. Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to highor lower-molecular-weight Vi. Infect Immun 1989, 57:3823-3827.
29. Hestrin S. The reaction of acetylcholine and other carboxylic acid derivatives with hydroxylamine, and its analytical application. J Biol Chem 1949, 180:249-261.
30. Atomic absorption spectrometry (2.2.23) Ph. Eur. 5.0 2006.
31. Lemercinier X., Martinez-Cabrera I., Jones C. Use and validation of an NMR test for the identity and O-acetyl content of the Salmonella typhi Vi capsular polysaccharide vaccine. Biologicals 2000, 28(1):17-24.
32. Stone A.L., Szu S.C. Application of optical properties of the Vi Capsular polysaccharide for quantitation of the Vi antigen in vaccines for typhoid fever. J. Clin. Microbiol. 1988, 26(4):719-725.
33. Kao G., Tsai C. Quantification of O-acetyl, N-acetyl and phosphate groups and determination of the extent of O-acetylation in bacterial vaccine polysaccharides by high-performance anion-exchange chromatography with conductivity detection (HPAEC-CD). Vaccine 2004, 22:335-344.
34. Stone A.L., Bradley D.F. Aggregation of cationic dyes on acid polysaccharides. I. Spectrophotometric titration with acridine orange and other metachromatic dyes. Biochim Biophys Acta 1967, 148:172-192.
35. Finn A. Bacterial polysaccharide-protein conjugate vaccines. Br Med Bull 2004, 70:1-14.
36. Lucas A.H., Apicella M.A., Taylor C.E. Carbohydrate moieties as vaccine candidates. Clin Infect Dis 2005, 41:705-712.
37. Vliegenthart J.F.G. Carbohydrate based vaccines. FEBS Lett 2006, 580:2945-2950.
38. Robbins J.B., Schneerson R., Anderson P., Smith D.H. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b: impact on public healthand implication for other polysaccharide-based vaccines. JAMA 1996, 276:1181-1185.
39. Chu C., Schneerson R., Robbins J.B., Rastogi S.C. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect Immun 1983, 40:245-256.
40. Szu S.C., Stone A.L., Robbins J.D., Schneerson R., Robbins J.B. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J Exp Med 1987, 166:1510-1524.
41. Szu S.C., Taylor D.N., Trofa A.C., Clemens J.D., Shiloach J., Sadoff J.C., et al. Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines. Infect Immun 1994, 62:4440-4444.
42. Cui C., Carbis R., An S.J., Jang H., Czerkinsky C., Szu S.C., et al. Physical and chemical characterization and immunologic properties of Salmonella enterica Serovar Typhi capsular polysaccharide-diphtheria toxoid conjugates. Clin Vac Immunol 2010, 17(1):73-79.
43. Singhal T., Amdekar Y., Agarwal R. IAP guidebook on immunization: IAP committee on immunization 2007-2008 2009, Jaypee, New Delhi, India, p. 57.
44. WHO TRS. Requirements for Vi polysaccharide typhoid vaccine. Adopted 1992, TRS No. 840, Annex 1.
45. Yu Ip C.C., Manam V., Hepler R., Hennessey J.P. Carbohydrate composition analysis of bacterial polysaccharides: optimized acid hydrolysis conditions for HPAEC-PAD analysis. Anal Biochem 1992, 201:343-349.
46. Talaga P., Vialle S., Moreau M. Development of a high-performance anion-exchange chromatography with pulsed-amperometric detection based quantification assay for pneumococcal polysaccharides and conjugates. Vaccine 2002, 20:2474-2484.
47. Tsai C.M., Gu X.X., Byrd A. Quantification of polysaccharide in Haemophilus influenzae type b conjugate and polysaccharide vaccines by high-performance anion-exchange chromatography with pulsed amperometric detection. Vaccine 1994, 12:700-706.
48. Ricci S., Bardotti A., D'Ascenzi S., Ravenscroft N. Development of a new method for the quantitative analysis of the extracellular polysaccharide of Neisseria meningitidis serogroup A by use of high-performance anion-exchange chromatography with pulsed-amperometric detection. Vaccine 2001, 19:1989-1997.